c. Whilst the mgmt. and board of directors have done nothing to suggest they shouldn't be trusted, and we've seen no evidence of prejudice of minority interests in favour of the interests of majority shareholders, the potential conflict of interest is obvious. From our interviews of sell-side analysts, we think the market is very sanguine re. this potential risk to minorities. We are more cautious, though believe the risk is sufficiently small not to outweigh the potential upside. Clearly, it needs to be monitored closely.
6. So why is NOS mispriced? What could cause the share price to re-rate?
a. NOS' strong operational performance through 2014-15A likely promoted a sense of complacency amongst NOS shareholders. Many investors probably saw NOS as a stable ‘deliver and beat’ growth story, which it very much has been, given its strong operational performance.
b. But after such smooth sailing, recent question marks re. (a) the Liga football rights situation, and (b) the poor way in which the growth capex step-up was communicated - with little explanation of the benefits - have spooked investors, some of which were probably quite focused on share price momentum, given NOS' strong run through 2014-15A.
c. We think these issues are likely to be speed bumps, rather than risks of permanent impairment of capital. We believe there is a good chance that 'normal service’ should resume in investors’ minds over the next few quarters.
d. We think that many investors have been too short-sighted re. appreciating the value uplift from the growth capex step up, with N2Y Op. FCF estimates likely to be cut by c. 15 to 20%, roughly in line with the share price decline of c. 25%.
i. Given the NPV positive nature of the investments, we think this is an over-reaction from Mr Market.
ii. The sell-side is also guilty here of raising capex estimates but not raising revenue estimates. A few have started to “get it” (as a result of having had follow up calls with management over the last month or so), but NOS’ small market cap. means it is far from the most important company in any sell-side analysts’ coverage universe, so they are in no real rush to update their analysis and/or forecasts. We believe this will happen over the coming months.
e. Management realise they have made a (rare) communication error with the market. There is good reason to believe, at the next earnings update, they will ram home the benefits of NOS' strategy, which should re-excite investors.
f. The growth opportunity in Corporate is also probably under-appreciated by the market. NOS has been doing well re. new contract wins, taking share from PT, as discussed above.
i. What's particularly interesting is that there is a lag between winning large corporate contracts and customers transferring, due to the complexity of large corporate customers' needs.
ii. A very strong 2015A for contract wins should actually filter into 2016E revenue growth, which we think might positively surprise investors. In simple terms, there looks scope for NOS to 'beat' on quarterly earnings.
g. NOS reports Q1 2016 earnings tomorrow. We believe there is decent scope for mgmt. to be more positive re. the growth capex plans (though we are probably setting ourselves up for a fall, posting the idea so close to earnings…! We’d suggest waiting to see how earnings come out before sharpening your pencils).
7. Margin of safety and potential returns
a. NOS looks attractively valued given its c. 5% mid-term revenue CAGR, c. 7% EBITDA CAGR, and > c. 25% uFCF CAGR (which is flattered by capex declining from temporarily elevated levels in 2014-16E, as the FTTH growth capex ceases).
b. If we assume revenue normalises to a c. 2% p.a. long-term growth rate and that drops down to mid-single digit EPS growth, we believe a fair eFCF multiple is c. 14 or 15x.
c. Applied to 2019E eFCF, that implies a fair share price in 2018E of c. €8.5 to 9.0. Add in c. €1.0 in cumm. dividends and SBBs (to maintain leverage of c. 2x ND/EBITDA) over that period and fair value per share in 2018E is c. €10.5.
d. This implies a N3Y potential IRR of c. 20%, which we believe is attractive given the risk profile of the business.
e. uFCF, EBITDA, P/E and Op. FCF multiples all support these IRR estimates (most imply slightly higher IRRs of c. 20 to 25%, in fact), as do peers’ trading valuation multiples, NOS' historical valuation multiples, and a DCF analysis.
f. Strong mid-term revenue and FCF growth, which has multiple drivers (i.e. is fairly resilient), means that we think we can argue that intrinsic value is increasing at somewhere between high single digits p.a. (in line w/ EBITDA growth) and low teens (with one eye on > 30% uFCF growth) on a mid-term basis (i.e. one to five years). This means that time should be our friend, even if the catalysts don’t eradicate the market’s mispricing of NOS’ shares in the short-term.